Profound Medical Corp. (NASDAQ:PROF) Q4 2023 Earnings Call Transcript

Page 6 of 6

Arun Menawat: That’s exactly the plan. That’s exactly the idea. And for a urologist to control from the very beginning to the end. And for all of the imaging to be in one place, so they can see all of the changes going on in the patient. And to be able to follow the patient for a year, two years, five years, that’s exactly the vision. And that’s exactly one of the reasons why. Dr. Emberton [ph] was one who provided the quote, because he’s one of the pioneering urologists in the world, really, who is focused on this strategy.

Brian Gagnon: Can a urology practice keep an MR busy enough on their own to justify the expense?

Arun Menawat: Yes. So we have done some of the initial economic models and we believe that is very, very likely. And again, part of it is because the fact that they can have revenue stream from every visit of the patient that they don’t have today, and part of it is the fact that they will own the patient, right. So right now, the patients come in and some of them will go to radiation and so on. I think they will actually be able to increase that number of patients they can treat with TULSA. And by the way there’s another revenue stream that we have not really quantified and at least so far is that if they have an MR there’s no reason why they couldn’t use it for other procedures like bladder cancer or cervical cancers and so on. So the answer to your question is most definitely they will be able to utilize that MR and economically justify it with relative ease quite frankly.

Brian Gagnon: Good. We’ll continue to watch and stay interested.

Arun Menawat: Thank you. Perfect. Thank you so much, Brian.

Operator: That concludes the question-and-answer session. This time I would like to turn the call back to Dr. Menawat for closing remarks.

Arun Menawat: Thank you so much for listening in the Q&A session and we’re looking forward to updating you at the end of Q1. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.

Follow Profound Medical Corp. (NASDAQ:PROF)

Page 6 of 6